New Aspects of VEGF, GABA, and Glutamate Signaling in the Neocortex of Human Temporal Lobe Pharmacoresistant Epilepsy Revealed by RT-qPCR Arrays
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Molecular Neuroscience
- Vol. 70 (6), 916-929
- https://doi.org/10.1007/s12031-020-01519-6
Abstract
In the epilepsy spectrum, temporal lobe epilepsy (TLE) is the most common and devastating focal and symptomatic epilepsy form in adults, where more than 30% of patients develop pharmacoresistance. It is not fully understood how the gene expression contributes to establishing an epileptic phenotype. Cerebrovascular remodeling directed by VEGF (vascular endothelial growth factor) signaling might modulate the synaptic neurotransmission in the epileptic brain. To address this question, the gene expression was profiled in biopsies of the temporal cortex from diagnosed patients with pharmacoresistant TLE that underwent surgical resection to seizure control. One hundred sixty-eight genes related to VEGF signaling and GABA and glutamate neurotransmissions were evaluated. Genes related to downstream signaling —phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinases (MAPK), and Janus-activated kinase/signal transducer and activator of transcription (JAK/STAT) pathways— and neurotransmitters metabolism were evaluated too. Thirty-nine genes were upregulated. The genes encoding for G protein q polypeptide, serine racemase, gephyrin, and glutamate/cystine antiporter system xCT appeared as novel upregulated genes in the pharmacoresistant TLE. ClueGO, a Cytoscape plugin, was used to build a gene network associated using Gene Ontology (GO) terminology. Enrichment analysis by ClueGO retrieves that positive regulation of endothelial cell proliferation, nerve development, and neuronal apoptosis were over-represented categories. In conclusion, VEGF signaling is confirmed as a relevant mediator in the pharmacoresistant TLE. In addition, the enrichment analysis applied to differentially expressed genes suggests new pharmacological targets to be assessed in the treatment of pharmacoresistant TLE. Results make up an approximation to better understand the epileptic brain and complement the available data.Keywords
Funding Information
- Consejo Nacional de Ciencia y Tecnología (177594)
This publication has 63 references indexed in Scilit:
- CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico dataBioinformatics, 2013
- A developmental and genetic classification for malformations of cortical development: update 2012Brain, 2012
- Temporal Lobe Epilepsy SemiologyEpilepsy Research and Treatment, 2012
- From mesial temporal lobe to temporoperisylvian seizures: A quantified study of temporal lobe seizure networksEpilepsia, 2010
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksBioinformatics, 2009
- Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factorsBrain, 2008
- Estimating the efficiency of benzodiazepines on GABAA receptors comprising γ1 or γ2 subunitsBritish Journal of Pharmacology, 2008
- Gene expression profile analysis of epilepsy-associated gangliogliomasNeuroscience, 2008
- Correlation of transcriptome profile with electrical activity in temporal lobe epilepsyNeurobiology of Disease, 2006
- Gene Ontology: tool for the unification of biologyNature Genetics, 2000